logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Clinical trials: this is how drugs and vaccines are designed

Medications and vaccines don’t come out of nowhere. They are not done in a rush and they are not due to commercial gimmicks. They are the result of years of research, analysis and checks that are carried out to assess the effect of these compounds on people’s health and the benefit obtained from them.

So whether it’s for the coronavirus vaccine or for a drug for a common disease or for cancer, any drug is subject to a clinical trial. But what is a clinical trial?

What is a clinical trial?
First of all we must understand exactly what this type of evaluation is. A clinical trial is a research study done in people to find out how a new drug or vaccine works against a disease. This type of analysis tries to analyze safety for people and its effectiveness. It can also be performed on a new drug or to compare with an existing one if it produces a greater benefit in the same disease or if it allows treating another.

Thus, the clinical trial aims to find out the efficacy of a drug, the adverse effects they may produce and what dose is the one that obtains the desired result.

“The discovery of a new drug begins in the laboratory, by identifying a new specific target, that is, where to attack to fight a disease. From there, a chemical or biological compound is designed that can attack that target and extensive tests are carried out in the laboratory and with computer simulations ”, they explain from Farmaindustria.

This preclinical phase continues with the evaluation of the compound in animals before the next step: designing a protocol in which the hypothesis to be tested is exposed, how many people will participate, how they will be selected and how the results will be analyzed. Once done, it is exposed to official bodies, health authorities and ethical committees; that is, to the Spanish Medicines Agency and the Ethics Committees for Medicines Research, which will give the green light to carry it out if they consider it so.

Participant safety and ethics
Clinical trials are supported by a series of good clinical practice guidelines. And for this reason, “the 1966 Helsinki Declaration, promulgated by the World Medical Association, lays the foundations of the ethical principles that all of us who are involved in medical research with human beings must follow,” explains Teresa Alonso, secretary to CuídatePlus scientist of the Spanish Society of Medical Oncology (SEOM), and medical oncologist of the Ramón y Cajal University Hospital, Madrid.

It is important, says Alonso, that it be understood that research is done with exquisite care and always guaranteeing the safety of the people who participate in it. In fact, before you can proceed to recruit patients to participate in a clinical trial, the research must be approved by an ethics committee of the center or hospital where it is to be carried out. “These committees are represented by professionals who are experts in different subjects and who analyze whether the indication for which a treatment is to be applied is within the standards of treatment for that disease; if the treatment and the security data they have are acceptable to administer it, if the center has the adequate infrastructure so that this clinical trial can be carried out… ”, says Alonso.

All this is essential to ensure that the research can be carried out, since in some cases the treatment is administered in the hospital quickly, in pill form, but in others injectables and advanced therapies are applied. It may also be necessary to analyze how people metabolize the treatment with the help of blood tests or imaging tests may be required or the patient may spend several hours or even a few days in the hospital.

Before the study is launched, the ethics committee must, necessarily, give the go-ahead. And from there you can start “the initial visits, in which the researcher can begin to offer patients to participate in the clinical trial,” explains Alonso. In addition, participants must sign an informed consent and their data will always be treated with confidentiality.

 

Related entries

24 September, 2025

Advanced therapies in lymphoma: six years of CAR-T that have changed patients’ lives


Leer más
17 September, 2025

The Community of Madrid aspires to become the “Silicon Valley” of the pharmaceutical sector.


Leer más
16 September, 2025

Farmaindustria welcomes the announcement by the Spanish Agency for Medicines and Health Products (AEMPS) to expand the accelerated assessment of early-stage clinical trials, as this strengthens the Spanish biomedical research ecosystem.


Leer más

Recent Posts

  • Advanced therapies in lymphoma: six years of CAR-T that have changed patients’ lives
  • The Community of Madrid aspires to become the “Silicon Valley” of the pharmaceutical sector.
  • Farmaindustria welcomes the announcement by the Spanish Agency for Medicines and Health Products (AEMPS) to expand the accelerated assessment of early-stage clinical trials, as this strengthens the Spanish biomedical research ecosystem.
  • Australia’s recipe for strengthening medical research capacity and leading the way into the next decade
  • Study identifies proteins involved in the efficacy of immunotherapy against blood cancer

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.